@article{MTMT:31356898,
	title = {Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus},
	url = {https://m2.mtmt.hu/api/publication/31356898},
	author = {Palma-Álvarez, Raul Felipe and Barta, Csaba and Carpentier, Pieter Jan and Carruthers, Susan and Crunelle, Cleo L. and Demetrovics, Zsolt and Dom, Geert and Faraone, Stephen V. and Franck, Johan and Johnson, Brian and Kapitány-Fövény, Máté and Kaye, Sharlene and Konstenius, Maija and Matthys, Frieda and Moggi, Franz and Møller, Merete and Schellekens, Arnt and Skutle, Arvid and van de Glind, Geurt and van Emmerik-van Oortmerssen, Katelijne and Verspreet, Sofie and Schoevers, Robert A. and Wallhed, Sara and Levin, Frances R. and Grau-López, Lara and Casas, Miguel and van den Brink, Wim and Ramos-Quiroga, Josep Antoni},
	doi = {10.1016/j.rpsm.2020.04.013},
	journal-iso = {REV PSIQUIATR SALUD},
	journal = {REVISTA DE PSIQUIATRIA Y SALUD MENTAL},
	volume = {16},
	unique-id = {31356898},
	issn = {1888-9891},
	year = {2023},
	eissn = {1989-4600},
	pages = {11-15},
	orcid-numbers = {Barta, Csaba/0000-0002-4350-8838; Demetrovics, Zsolt/0000-0001-5604-7551; Kapitány-Fövény, Máté/0000-0002-0850-8699}
}

@article{MTMT:33538163,
	title = {Cell-Penetrating Dabcyl-Containing Tetraarginines with Backbone Aromatics as Uptake Enhancers},
	url = {https://m2.mtmt.hu/api/publication/33538163},
	author = {Yousef, M. and Szabó, Ildikó and Murányi, József and Illien, Françoise and Soltész, Dóra and Bató, Csaba and Tóth, Gabriella and Batta, Gyula Gábor (Ifj.) and Nagy, Péter and Sagan, Sandrine and Bánóczi, Zoltán},
	doi = {10.3390/pharmaceutics15010141},
	journal-iso = {PHARMACEUTICS},
	journal = {PHARMACEUTICS},
	volume = {15},
	unique-id = {33538163},
	abstract = {Cell-penetrating peptides represent an emerging class of carriers capable of effective cellular delivery. This work demonstrates the preparation and investigation of efficient CPPs. We have already shown that the presence of 4-((4-(dimethylamino)phenyl)azo)benzoic acid (Dabcyl) and Trp greatly increase the uptake of oligoarginines. This work is a further step in that direction. We have explored the possibility of employing unnatural, aromatic amino acids, to mimic Trp properties and effects. The added residues allow the introduction of aromaticity, not as a side-chain group, but rather as a part of the sequence. The constructs presented exceptional internalization on various cell lines, with an evident structure–activity relationship. The CPPs were investigated for their entry mechanisms, and our peptides exploit favorable pathways, yet one of the peptides relies highly on direct penetration. Confocal microscopy studies have shown selectivity towards the cell lines, by showing diffuse uptake in FADU cells, while vesicular uptake takes place in SCC-25 cell line. These highly active CPPs have proved their applicability in cargo delivery by successfully delivering antitumor drugs into MCF-7 and MDA-MB-231 cells. The modifications in the sequences allow the preparation of short yet highly effective constructs able to rival the penetration of well-known CPPs such as octaarginine (Arg8).},
	year = {2023},
	eissn = {1999-4923},
	orcid-numbers = {Szabó, Ildikó/0000-0002-9844-7841; Murányi, József/0000-0001-5672-6482; Batta, Gyula Gábor (Ifj.)/0000-0001-8735-6920; Nagy, Péter/0000-0002-7466-805X; Bánóczi, Zoltán/0000-0003-1880-4042}
}

@article{MTMT:33541689,
	title = {Protein Kinase D3 (PKD3) Requires Hsp90 for Stability and Promotion of Prostate Cancer Cell Migration},
	url = {https://m2.mtmt.hu/api/publication/33541689},
	author = {Varga, Attila and Nguyen, Minh Tu and Pénzes, Kinga and Bátai, Bence and Gyulavári, Pál and Gurbi, Bianka and Murányi, József and Csermely, Péter and Csala, Miklós and Vántus, Tibor and Sőti, Csaba},
	doi = {10.3390/cells12020212},
	journal-iso = {CELLS-BASEL},
	journal = {CELLS},
	volume = {12},
	unique-id = {33541689},
	abstract = {Prostate cancer metastasis is a significant cause of mortality in men. PKD3 facilitates tumor growth and metastasis, however, its regulation is largely unclear. The Hsp90 chaperone stabilizes an array of signaling client proteins, thus is an enabler of the malignant phenotype. Here, using different prostate cancer cell lines, we report that Hsp90 ensures PKD3 conformational stability and function to promote cancer cell migration. We found that pharmacological inhibition of either PKDs or Hsp90 dose-dependently abrogated the migration of DU145 and PC3 metastatic prostate cancer cells. Hsp90 inhibition by ganetespib caused a dose-dependent depletion of PKD2, PKD3, and Akt, which are all involved in metastasis formation. Proximity ligation assay and immunoprecipitation experiments demonstrated a physical interaction between Hsp90 and PKD3. Inhibition of the chaperone–client interaction induced misfolding and proteasomal degradation of PKD3. PKD3 siRNA combined with ganetespib treatment demonstrated a specific involvement of PKD3 in DU145 and PC3 cell migration, which was entirely dependent on Hsp90. Finally, ectopic expression of PKD3 enhanced migration of non-metastatic LNCaP cells in an Hsp90-dependent manner. Altogether, our findings identify PKD3 as an Hsp90 client and uncover a potential mechanism of Hsp90 in prostate cancer metastasis. The molecular interaction revealed here may regulate other biological and pathological functions.},
	year = {2023},
	eissn = {2073-4409},
	orcid-numbers = {Nguyen, Minh Tu/0000-0003-1653-8377; Gyulavári, Pál/0000-0002-5850-0441; Gurbi, Bianka/0000-0002-5635-6255; Csermely, Péter/0000-0001-9234-0659; Csala, Miklós/0000-0002-3829-4361; Vántus, Tibor/0000-0002-7894-017X; Sőti, Csaba/0000-0002-4057-7678}
}

@article{MTMT:33610921,
	title = {MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers},
	url = {https://m2.mtmt.hu/api/publication/33610921},
	author = {Gurbi, Bianka and Brauswetter, Diána and Pénzes, Kinga and Varga, Attila and Krenács, Tibor and Dános, Kornél and Birtalan, Ede and Tamás, László and Csala, Miklós},
	doi = {10.3390/ijms24032782},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {33610921},
	issn = {1661-6596},
	abstract = {The poor prognosis of head-and-neck squamous cell carcinoma (HNSCC) is partly due to the lack of reliable prognostic and predictive markers. The Ras/Raf/MEK/ERK signaling pathway is often activated by overexpressed epidermal growth factor receptor (EGFR) and stimulates the progression of HNSCCs. Our research was performed on three human papillomavirus (HPV)-negative HNSCC-cell lines: Detroit 562, FaDu and SCC25. Changes in cell viability upon EGFR and/or MEK inhibitors were measured by the MTT method. The protein-expression and phosphorylation profiles of the EGFR-initiated signaling pathways were assessed using Western-blot analysis. The EGFR expression and pY1068-EGFR levels were also studied in the patient-derived HNSCC samples. We found significant differences between the sensitivity of the tumor-cell lines used. The SCC25 line was found to be the most sensitive to the MEK inhibitors, possibly due to the lack of feedback Akt activation through EGFR. By contrast, this feedback activation had an important role in the FaDu cells. The observed insensitivity of the Detroit 562 cells to the MEK inhibitors might have been caused by their PIK3CA mutation. Among HNSCC cell lines, EGFR-initiated signaling pathways are particularly versatile. An ERK/EGFR feedback loop can lead to Akt-pathway activation upon MEK inhibition, and it is related not only to increased amounts of EGFR but also to the elevation of pY1068-EGFR levels. The presence of this mechanism may justify the combined application of EGFR and MEK inhibitors.},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Gurbi, Bianka/0000-0002-5635-6255; Krenács, Tibor/0000-0001-9164-065X; Dános, Kornél/0000-0002-3829-8266; Birtalan, Ede/0000-0002-5699-3545; Tamás, László/0000-0003-3723-9149; Csala, Miklós/0000-0002-3829-4361}
}

@article{MTMT:32154300,
	title = {Internationale Konsenserklärung zu Screening, Diagnostik und Behandlung von Jugendlichen und Heranwachsenden mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung und gleichzeitigen Störungen durch Substanzgebrauch},
	url = {https://m2.mtmt.hu/api/publication/32154300},
	author = {Özgen, Heval and Spijkerman, Renske and Noack, Moritz and Holtmann, Martin and Schellekens, Arnt S A and van de Glind, Geurt and Banaschewski, Tobias and Barta, Csaba and Begeman, Alex and Casas, Miguel and Crunelle, Cleo L and Daigre Blanco, Constanza and Dalsgaard, Søren and Demetrovics, Zsolt and den Boer, Jacomine and Dom, Geert and Eapen, Valsamma and Faraone, Stephen V and Franck, Johan and González, Rafael A and Grau-López, Lara and Groenman, Annabeth P and Hemphälä, Malin and Icick, Romain and Johnson, Brian and Kaess, Michael and Kapitány-Fövény, Máté and Kasinathan, John G and Kaye, Sharlene S and Kiefer, Falk and Konstenius, Maija and Levin, Frances R and Luderer, Mathias and Martinotti, Giovanni and Matthys, Frieda I A and Mészáros, Gergely and Moggi, Franz and Munasur-Naidoo, Ashmita P and Post, Marianne and Rabinovitz, Sharon and Ramos-Quiroga, J Antoni and Sala, Regina and Shafi, Abu and Slobodin, Ortal and Staal, Wouter G and Thomasius, Rainer and Truter, Ilse and van Kernebeek, Michiel W and Velez-Pastrana, Maria C and Vollstädt-Klein, Sabine and Vorspan, Florence and Young, Jesse T and Yule, Amy and van den Brink, Wim and Hendriks, Vincent},
	doi = {10.1024/1422-4917/a000828},
	journal-iso = {Z KINDER JUG-PSYCH},
	journal = {ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE},
	volume = {50},
	unique-id = {32154300},
	issn = {1422-4917},
	abstract = {International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder Abstract.Background: Childhood attention-deficit/hyperactivity disorder (ADHD) is a risk factor for substance misuse and substance use disorder (SUD) in adolescence and (early) adulthood. ADHD and SUD also frequently co-occur in treatment-seeking adolescents, which complicates diagnosis and treatment and is associated with poor treatment outcomes. Research on the effect of treatment of childhood ADHD on the prevention of adolescent SUD is inconclusive, and studies on the diagnosis and treatment of adolescents with ADHD and SUD are scarce. Thus, the available evidence is generally not sufficient to justify robust treatment recommendations. Objective: The aim of the study was to obtain a consensus statement based on a combination of scientific data and clinical experience. Method: A modified Delphi study to reach consensus based upon the combination of scientific data and clinical experience with a multidisciplinary group of 55 experts from 17 countries. The experts were asked to rate a set of statements on the effect of treatment of childhood ADHD on adolescent SUD and on the screening, diagnosis, and treatment of adolescents with comorbid ADHD and SUD. Results: After 3 iterative rounds of rating and adapting 37 statements, consensus was reached on 36 of these statements representing 6 domains: general (n = 4), risk of developing SUD (n = 3), screening and diagnosis (n = 7), psychosocial treatment (n = 5), pharmacological treatment (n = 11), and complementary treatments (n = 7). Routine screening is recommended for ADHD in adolescent patients in substance abuse treatment and for SUD in adolescent patients with ADHD in mental healthcare settings. Long-acting stimulants are recommended as the first-line treatment of ADHD in adolescents with concurrent ADHD and SUD, and pharmacotherapy should preferably be embedded in psychosocial treatment. The only remaining no-consensus statement concerned the requirement of abstinence before starting pharmacological treatment in adolescents with ADHD and concurrent SUD. In contrast to the majority, some experts required full abstinence before starting any pharmacological treatment, some were against the use of stimulants in the treatment of these patients (independent of abstinence), while some were against the alternative use of bupropion. Conclusion: This international consensus statement can be used by clinicians and patients together in a shared decision-making process to select the best interventions and to reach optimal outcomes in adolescent patients with concurrent ADHD and SUD.},
	keywords = {DISORDER; Adolescents; Substance use disorder; CONSENSUS STATEMENT; Attention-deficit/hyperactivity; Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung; Jugendliche; Konsenserklärung; Störungen durch Substanzgebrauch},
	year = {2022},
	eissn = {1664-2880},
	pages = {54-67},
	orcid-numbers = {Barta, Csaba/0000-0002-4350-8838; Demetrovics, Zsolt/0000-0001-5604-7551; Kapitány-Fövény, Máté/0000-0002-0850-8699}
}

@article{MTMT:32574856,
	title = {Production of NOS2 and inflammatory cytokines is reduced by selected protein kinase inhibitors with partial repolarization of HL-60 derived and human blood macrophages},
	url = {https://m2.mtmt.hu/api/publication/32574856},
	author = {Bőgel, Gábor and Murányi, József and Szokol, Bálint and Kukor, Zoltán and Móra , István András and Kardon Tamás, Zoltán and Őrfi, László and Hrabák, András},
	doi = {10.1016/j.heliyon.2021.e08670},
	journal-iso = {HELIYON},
	journal = {HELIYON},
	volume = {8},
	unique-id = {32574856},
	year = {2022},
	eissn = {2405-8440},
	orcid-numbers = {Bőgel, Gábor/0000-0002-7677-6855; Kukor, Zoltán/0000-0002-7250-2160; Őrfi, László/0000-0001-6149-2385; Hrabák, András/0000-0002-7818-6509}
}

@{MTMT:32683354,
	title = {Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity.. WO2022029459A1},
	url = {https://m2.mtmt.hu/api/publication/32683354},
	author = {Csámpai, Antal and Bárány, Péter Tibor and Czuczi, Tamas and Kovacs, Imre and Adamis, Balint and Nemeth, Zsofia and Murányi, József and Olahne, Szabo Rita and Bosze, Szilvia and Mezo, Gabor and Kőhidai, László and Lajkó, Eszter and Takács, Angéla and Láng, Orsolya and Mezo, Diana},
	unique-id = {32683354},
	abstract = {The present invention relates to compds. of formula (I) (I) or pharmaceutically acceptable salts, and stereoisomers thereof, including enantiomers, racemic mixts., mixts. of enantiomers, or combinations thereof, which are applicable for use in treating cancer diseases. The present invention further relates to a pharmaceutical compn. comprising the above compds. [on SciFinder(R)]},
	year = {2022},
	pages = {91pp.},
	orcid-numbers = {Csámpai, Antal/0000-0003-2107-7309; Kőhidai, László/0000-0002-9002-0296; Lajkó, Eszter/0000-0002-4796-4646; Takács, Angéla/0000-0002-8912-8216; Láng, Orsolya/0000-0002-2787-2154}
}

@article{MTMT:32782717,
	title = {Synthesis and Antiproliferative Activity of Novel Imipridone–Ferrocene Hybrids with Triazole and Alkyne Linkers},
	url = {https://m2.mtmt.hu/api/publication/32782717},
	author = {Czuczi, Tamás and Murányi, József and Bárány, Péter Tibor and Móra , István András and Borbély, Adina Noémi and Csala, Miklós and Csámpai, Antal},
	doi = {10.3390/ph15040468},
	journal-iso = {PHARMACEUTICALS-BASE},
	journal = {PHARMACEUTICALS},
	volume = {15},
	unique-id = {32782717},
	year = {2022},
	eissn = {1424-8247},
	orcid-numbers = {Borbély, Adina Noémi/0000-0002-5506-6555; Csala, Miklós/0000-0002-3829-4361; Csámpai, Antal/0000-0003-2107-7309}
}

@article{MTMT:30972609,
	title = {Arterial Tortuosity Syndrome: An Ascorbate Compartmentalization Disorder?},
	url = {https://m2.mtmt.hu/api/publication/30972609},
	author = {Boel, Annekatrien and Veszelyi, Krisztina Nóra and Németh, Csilla Emese and Beyens, Aude and Willaert, Andy and Coucke, Paul and Callewaert, Bert and Margittai, Éva},
	doi = {10.1089/ars.2019.7843},
	journal-iso = {ANTIOXID REDOX SIGNAL},
	journal = {ANTIOXIDANTS & REDOX SIGNALING},
	volume = {34},
	unique-id = {30972609},
	issn = {1523-0864},
	abstract = {Significance:                     Cardiovascular disorders are the most important cause of morbidity and mortality in the Western world. Monogenic developmental disorders of the heart and vessels are highly valuable to study the physiological and pathological processes in cardiovascular system homeostasis. The arterial tortuosity syndrome (ATS) is a rare, autosomal recessive connective tissue disorder showing lengthening, tortuosity, and stenosis of the large arteries, with a propensity for aneurysm formation. In histopathology, it associates with fragmentation and disorganization of elastic fibers in several tissues, including the arterial wall. ATS is caused by pathogenic variants in SLC2A10 encoding the facilitative glucose transporter (GLUT)10.                         Critical Issues:                     Although several hypotheses have been forwarded, the molecular mechanisms linking disrupted GLUT10 activity with arterial malformations are largely unknown.                         Recent Advances:                     The vascular and systemic manifestations and natural history of ATS patients have been largely delineated. GLUT10 was identified as an intracellular transporter of dehydroascorbic acid, which contributes to collagen and elastin cross-linking in the endoplasmic reticulum, redox homeostasis in the mitochondria, and global and gene-specific methylation/hydroxymethylation affecting epigenetic regulation in the nucleus. We revise here the current knowledge on ATS and the role of GLUT10 within the compartmentalization of ascorbate in physiological and diseased states.                         Future Directions:                     Centralization of clinical, treatment, and outcome data will enable better management for ATS patients. Establishment of representative animal disease models could facilitate the study of pathomechanisms underlying ATS. This might be relevant for other forms of vascular dysplasia, such as isolated aneurysm formation, hypertensive vasculopathy, and neovascularization. Antioxid. Redox Signal. 00, 000-000.},
	keywords = {ASCORBATE; Compartmentalization; arterial tortuosity syndrome; GLUT10},
	year = {2021},
	eissn = {1557-7716},
	pages = {875-889},
	orcid-numbers = {Veszelyi, Krisztina Nóra/0000-0003-1137-2937; Margittai, Éva/0000-0003-0841-0613}
}

@article{MTMT:31363364,
	title = {Vitamin C and cell death},
	url = {https://m2.mtmt.hu/api/publication/31363364},
	author = {Szarka, András and Kapuy, Orsolya and Lőrincz, Tamás and Bánhegyi, Gábor},
	doi = {10.1089/ars.2019.7897},
	journal-iso = {ANTIOXID REDOX SIGNAL},
	journal = {ANTIOXIDANTS & REDOX SIGNALING},
	volume = {34},
	unique-id = {31363364},
	issn = {1523-0864},
	abstract = {Persistent oxidative stress is a common feature of cancer cells, giving a specific weapon to selectively eliminate them. Ascorbate in pharmacologic concentration can contribute to the suspended formation of hydroxyl radical via the Fenton reaction, thus it can be an important element of the oxidative stress therapy against cancer cells. Recent Advances: The main components of ascorbate induced cell death are DNA double-strand breaks via the production of hydroxyl radical and ATP depletion due to the activation of PARP1. Presumably, DNA damage can be the primary contributor to the anti-cancer activity of pharmacologic ascorbate, as opposed to the rupture of bioenergetics. The caspase independency of high dose ascorbate induced cell death proposed the possible involvement of several types of cell death such as ferroptosis, necroptosis and autophagy.Ascorbate can target at least two key molecular features of cancer cells as a part of the anti-cancer therapy: the intrinsic or acquired resistance to cell death and the dysregulated metabolism of cancer cells. It seems probable that different concentrations of ascorbate alter the nature of induced cell death. Autophagy and necroptosis may play a role at intermediate concentrations, but caspase independent apoptosis may dominate at higher concentrations. However, ascorbate behaves as an effective inhibitor of ferroptosis that may have crucial importance in its possible clinical application.The elucidation of the details and the links between high dose ascorbate induced cancer selective cell death mechanisms may give us a tool to form and apply synergistic cancer therapies.},
	year = {2021},
	eissn = {1557-7716},
	pages = {831-844},
	orcid-numbers = {Szarka, András/0000-0001-6594-254X; Kapuy, Orsolya/0000-0002-8484-4504; Bánhegyi, Gábor/0000-0001-7559-0066}
}